SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Mining Inc

Cipher Mining is drawing investor focus as it executes a strategic pivot from crypto mining to long-term, hyperscale AI data center infrastructure through multi-year agreements with major cloud providers. The community is closely monitoring the development of these power-intensive facilities and actively discussing the stock's potential for a valuation re-rating as it moves toward fixed-contract revenue models.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors weigh significant cash holdings and potential acquisition strategies against a lack of immediate operational guidance following the latest earnings release. The community remains deeply polarized, with active debates centered on skepticism toward leadership, frustration over prolonged price stagnation, and persistent hopes for a major catalyst to trigger a move.

🌍 Introduction: A Legendary Icon, Reimagined for the Future The SEAMANIA Protocol, led by SEAMAN Cult, aims to revive one of SEGA Dreamcast's most iconic and best-selling game titles with AI integration—a worldwide cultural phenomenon that won numerous awards in the U.S. and Japan. More than just a game, SEAMAN was the world’s first AI-powered interactive experience, enabling voice-based conversations long before the AI revolution.    Now, SEAMAN returns not as a mere game, but as an advanced AI agent, blending nostalgia with cutting-edge technology. This human-faced fish is reborn as a deeply intelligent, emotionally responsiveAI, offering limitless customization and integration into the modern digital world.  With GenAI-powered customization, users can create their own SEAMAN AI, shaping it into a cherished lostone, a favorite celebrity, or even historical figures. This is no longer a game—it's an AI-driven personal companion and the digital evolution for human interaction.    🔥 Concept: The Wisdom of a Legendary AI-powered Companion At the core of the SEAMANIA Protocol lies the legendary Seaman—a mystical, human-faced fish endowed withancient wisdom and the ability to understand human language. More than just an AI, it is your trustedadvisor, best friend, therapist, personal cheerleader, witty conversationalist, intelligent guide, SEAMANIA is a life coach. Housed in your own digital aquarium, your SEAMAN AI reduces stress, combats loneliness, and guides humanity towards a brighter future. Imagine an AI companion that doesn’t just respond but truly understands, entertains, and supports you—blending humor, sarcasm, and wisdom.

SEAMANIA

SEAMANIA is trending as a highly speculative meme coin, with community members actively coordinating small-increment buying campaigns to trigger rapid price surges. Investors are drawing parallels to other volatile assets while expressing high-stakes optimism about the potential for massive percentage gains despite skepticism regarding its long-term viability.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is surging following a definitive agreement to be acquired by Merck in an all-cash deal valued at approximately $6.7 billion, a move aimed at bolstering Merck's oncology pipeline. Investors are celebrating the substantial premium and the validation of TERN-701's potential in treating chronic myeloid leukemia, while community discussions highlight both the long-awaited payoff for early longs and speculation regarding potential future targets within the biotech sector.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Chewy Inc - Ordinary Shares - Class A

Chewy Inc

Chewy is trending as investors weigh a confident outlook for 2026 and positive margin growth against ongoing concerns regarding market volatility and competitive pressure from retail giants. The community remains divided, with some traders optimistic about potential breakouts above key technical support levels, while others express frustration over recent price consolidation and the stock's sluggish performance despite steady business fundamentals.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is trending as investors compare its 21 million token supply and decentralization to Bitcoin, labeling it the "Bitcoin of AI." The community is heavily focused on the upcoming supply halving, the rapid growth of autonomous subnets within its ecosystem, and strong institutional interest through emerging investment vehicles.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is currently in the spotlight as investors process a combative rebuttal to a recent short report, with the community actively debating the company's long-term financial health versus the risks of activist short-selling tactics. While some investors remain highly convicted in the firm's fundamental growth trajectory and pending catalysts, the stock's recent volatility has triggered urgent calls for management to provide further clarity and reassure shareholders.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is drawing significant investor attention as rumors of a potential SpaceX IPO intensify, with traders debating whether to buy the stock as a proxy for SpaceX and Anthropic exposure or to avoid it due to its high trading premium relative to net asset value. Community sentiment remains polarized, as bulls focus on the fund's high-profile private tech holdings, while bears emphasize its premium-to-NAV disconnect and the risks associated with holding a closed-end fund.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

The SPERMWHALE token is trending as traders debate whether its chart structure signals a breakout or a potential rug pull. The community remains deeply divided, with some investors betting on explosive upside while others warn of extreme volatility and artificial volume manipulation typical of meme coin cycles.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck & Co. has reached a definitive agreement to acquire Terns Pharmaceuticals in a multi-billion-dollar cash deal, signaling a major strategic push to bolster its oncology pipeline ahead of the looming patent expiration for its flagship drug, Keytruda. Investors and community members are actively discussing the premium valuation and the potential for increased competition in the cancer drug market as Merck looks to secure its long-term growth and leadership in the space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Identiv (NASDAQ:INVE) Posts Earnings Results

Identiv (NASDAQ:INVE - Get Free Report) posted its quarterly earnings data on Thursday. The technology company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of...

Identiv Q4 Earnings Call Highlights

Identiv (NASDAQ:INVE) reported fourth quarter and fiscal year 2025 results that management said exceeded internal guidance, highlighting progress on its Perform, Accelerate, and Transform (PAT...

Identiv, Inc. (INVE) Reports Q4 Loss, Tops Revenue Estimates

Identiv (INVE) delivered earnings and revenue surprises of +5.88% and +8.18%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Identiv, Inc. (NASDAQ:INVE) Short Interest Down 46.1% in February

Identiv, Inc. (NASDAQ:INVE - Get Free Report) was the recipient of a large decrease in short interest during the month of February. As of February 27th, there was short interest totaling 140,830...

Identiv Reports Fourth Quarter and Fiscal Year 2025 Financial Results, Exceeds Q4 Guidance and Signs Multi-Year Supply Agreement

Identiv Reports Fourth Quarter and Fiscal Year 2025 Financial Results, Exceeds Q4 Guidance and Signs Multi-Year Supply Agreement Identiv Reports Fourth Quarter and Fiscal Year 2025 Financial Results...

Identiv Announces Exclusive Agreement to Develop and Supply BLE Smart Labels, Advancing Its Perform, Accelerate, and Transform Growth Strategy

Identiv Announces Exclusive Agreement to Develop and Supply BLE Smart Labels, Advancing Its Perform, Accelerate, and Transform Growth Strategy Identiv Announces Exclusive Agreement to Develop and...

Identiv (INVE) Projected to Post Earnings on Wednesday

Identiv (NASDAQ:INVE) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 4. (View Earnings Report at...

Identiv Sets Fourth Quarter and Fiscal Year 2025 Earnings Call for Thursday, March 12, 2026, at 5:00 PM EDT

Identiv Sets Fourth Quarter and Fiscal Year 2025 Earnings Call for Thursday, March 12, 2026, at 5:00 PM EDT Identiv Sets Fourth Quarter and Fiscal Year 2025 Earnings Call for Thursday, March 12...

Identiv, Inc. (NASDAQ:INVE) Short Interest Update

Identiv, Inc. (NASDAQ:INVE - Get Free Report) was the target of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 267,123 shares...

Identiv, Inc. (NASDAQ:INVE - Get Free Report) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totaling 194,308 shares, an increase...

Identiv, Inc. engages in the provision of physical security and secure identification solutions. Its products include physical access control and video, logical access control, credentials, and RFID inlays and tags. The firm serves the government, healthcare, airports and aviation, and education. It operates through the Identity and Premises segments. The Identity segment consists of products and solutions enabling secure access to information serving the logical access and cyber security market and protecting assets and objects in the Internet of Things with radio frequency identification. The Premises segment offers solutions to address the premises security market for government and enterprise, including access control, video surveillance, analytics, customer experience, and other applications. The company was founded in 1990 and is headquartered in Fremont, CA.

INVE
Identiv Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INVE News

INVEIdentiv Inc